Simulations Plus Announces Completion of Acquisition by Altaris
Key Highlights
- ➤Simulations Plus acquisition by Altaris completed at $18.50 cash per share
- ➤Simulations Plus becomes privately held; Nasdaq trading will cease
- ➤Simulations Plus combines with Altaris portfolio company Chemical Computing Group
- ➤Combined platform spans drug discovery, modeling, simulation, and development
Expert Statements
Shawn O'Connor, Chief Executive Officer of Simulations Plus
“Today marks an exciting new chapter for Simulations Plus”
Shawn O'Connor, Chief Executive Officer of Simulations Plus
“Our mission has always been to help our customers accelerate the discovery, development, and commercialization of innovative therapies through advanced modeling, simulation, and AI-driven technologies.”
Shawn O'Connor, Chief Executive Officer of Simulations Plus
“By joining CCG, we believe we are well positioned to accelerate investment in innovation, expand our capabilities, and expand the solution we provide to customers across the biopharmaceutical ecosystem.”
Shawn O'Connor, Chief Executive Officer of Simulations Plus
“We want to thank our employees, customers, partners, and shareholders for their support throughout our journey as a public company.”
Paul Labute, Chief Executive Officer of Chemical Computing Group
“We are delighted to welcome the Simulations Plus team to CCG”
Paul Labute, Chief Executive Officer of Chemical Computing Group
“Simulations Plus has established itself as a trusted leader in biosimulation and model-informed drug development, supported by its science, differentiated technology, and deep customer relationships.”
Paul Labute, Chief Executive Officer of Chemical Computing Group
“We look forward to partnering with the company's talented team to support continued growth and innovation while advancing solutions that help improve the efficiency and success of drug development.”
Simulations Plus Announces Completion of Acquisition by Altaris
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced the completion of its acquisition by affiliates of Altaris, LLC ("Altaris"), an investment firm focused exclusively on the healthcare industry.
Get started
Create a free account to read the full story.